FrancophonIA/ELRC3.0 huggingface dataset:
English: In patients receiving a hepatic enzyme inducer, initiation of Seroquel XR treatment should only occur if the physician considers that the benefits of Seroquel XR outweigh the risks of removing the hepatic enzyme inducer.
Estonian: Maksaensüüme indutseerivaid ravimeid kasutavatel patsientidel tuleb ravi SEROQUEL XRga alustada ainult juhul, kui SEROQUEL XR ravist saadav kasu kaalub üles võimaliku riski, mis tekib maksaensüümide indutseerija eemaldamisest.
English: In the relapse prevention study (monotherapy), also in unrestricted MDD population but after 14 to 26 weeks of open label treatment, responders were randomised to continuing quetiapine treatment or placebo for up to 52 weeks and showed significant and clinically relevant results in favour of active treatment.
Estonian: Relapside ennetamise uuringus (monoteraapia) samuti piiranguteta raskete depressiivhäiretega populatsioonis, kuid pärast 14-26-nädalast avatud menetlusel tehtud ravi, randomiseeriti ravile reageerinud patsiendid kuni 52 nädalaks kvetiapiini- või platseeborühma.
English: Quetiapine has no appreciable affinity at muscarinic or benzodiazepine receptors.
Estonian: Kvetiapiin ei oma märgatavat afiinsust muskariinvõi bensodiasepiini retseptorite suhtes.
English: In a short-term placebo-controlled monotherapy trial with Seroquel in children and adolescent patients (10-17 years of age) with bipolar mania, the aggregated incidence of extrapyramidal symptoms was 3.6% for quetiapine and 1.1% for placebo.
Estonian: Lühiajalises platseebo kontrolliga monoravi uuringus lastest ja noorukitest bipolaarse mania patsientidel (10…17-aastased) oli ekstrapüramidaalsümptomite summeeritud sagedus 3,6% kvetiapiini rühmas ning 1,1% platseebo rühmas.
English: • treatment of major depressive episodes in bipolar disorder.
Estonian: • bipolaarse häirega seotud raskete depressiooniepisoodide ravi;
English: The most commonly noted adverse reactions with quetiapine were dry mouth, sedation, and somnolence while nausea and headache were more commonly noted with the active controls.
Estonian: Kvetiapiini kõige sagedamini esinenud kõrvalnähud olid suukuivus, sedatsioon ja unisus ning aktiivsete kontrollide sagedaimad kõrvalnähud olid iiveldus ja peavalu.
English: • Boys and girls to have swelling of breasts and unexpectedly produce breast milk
Estonian: -poisslastel ja tütarlastel rindade turset ja ootamatut eritist rinnast;
English: If you are, Seroquel XR should not be taken because the group of medicines that Seroquel XR belongs to may increase the risk of stroke, or in some cases the risk of death, in elderly people with dementia.
Estonian: Sel juhul ei tohiks Seroquel XR kasutada, kuna Seroquel XR võib suurendada ajurabanduse tekkeohtu ning üksikjuhtudel surmaohtu.
English: • treatment of Schizophrenia, including o preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR.
Estonian: • skisofreenia ravi, sh relapside ennetamine stabiilsetel skisofreenilistel patsientidel, kellele ravim
English: Tablet Strength
Estonian: Tableti suurus
English: There are no active controlled on long-term safety data in MDD and the placebo controlled randomised withdrawal data are of limited value due to decreased numbers of patients over time.
Estonian: Platseebokontrollitud randomiseeritud ravi katkestamise uuringute andmete väärtus on piiratud, sest patsientide arv väheneb aja jooksul.
English: • Do not use Seroquel XR after the expiry date which is stated on the container after EXP.
Estonian: Ärge kasutage Seroquel XRi pärast kõlblikkusaega, mis on märgitud pakendil.
English: Steadystate peak molar concentrations of the active metabolite norquetiapine are 35% of that observed for quetiapine.
Estonian: Aktiivse metaboliidi norkvetiapiini maksimaalne molaarne kontsentratsioon pärast tasakaalukontsentratsiooni saavutamist moodustab 35% kvetiapiini omast.
English: Immune system disorders Uncommon:
Estonian: Immuunsüsteemi häired:
English: Endocrine disorders
Estonian: Endokriinsed häired:
English: Renal impairment: Dosage adjustment is not necessary in patients with renal impairment.
Estonian: Neerupuudulikkusega patsiendid Annuse kohandamine ei ole vajalik.
English: Quetiapine and the active human plasma metabolite, norquetiapine interact with a broad range of neurotransmitter receptors.
Estonian: Kvetiapiin ning selle aktiivne metaboliit plasmasnorkvetiapiin toimivad laia skaalasse neuromediaatorite retseptoreisse.
English: In short-term clinical trials with Seroquel in paediatric patients (10-17 years of age), 17% of quetiapine treated patients and 2.5% of placebo treated patients gained ≥7% of their body weight.
Estonian: Pediaatriliste patsientide (10…17-aastased) lühiajalistes kliinilistes uuringutes, võtsid ≥7% oma kehakaalus juurde 17% kvetiapiinravi saanud patsientidest ja 2,5% platseebot saanutest.
English: The target population have not been studied in the placebo controlled monotherapy studies and the potential better safety profile of alternative antidepressants precluded a positive balance between efficacy and safety in the claimed indication.
Estonian: Alternatiivsete antidepressantide võimalik parem ohutusprofiil oli takistuseks soovitud näidustuse positiivsele efektiivsuse ja ohutuse tasakaalule.
English: Eosinophilia, Thrombocytopenia
Estonian: Eosinofiilia, trombotsütopeenia
English: As Seroquel XR is indicated for the treatment of schizophrenia, bipolar disorder and add-on treatment of major depressive episodes in patients with MDD, the safety profile should be considered with respect to the individual patient's diagnosis and the dose being administered.
Estonian: SEROQUEL XR on näidustatud skisofreenia, bipolaarse häire ja depressiooniga patsientidel, mistõttu tuleb tähelepanu pöörata ohutusalasele teabele, mis on seotud patsiendi diagnoosi ja manustatava annusega.
English: Abnormal dreams and nightmares Suicidal ideation and suicidal behaviour20
Estonian: Hirmuunenäod Suitsiidi ettekujutamine ja suitsidaalne käitumine (21)
English: Clinicians should therefore ensure that the lowest effective dose, starting with 50 mg/day, is used for treatment.
Estonian: Raviarst peab veenduma, et raviks kasutatakse madalaimat efektiivset annust, alustades 50 mg/ööpäevas.
English: (11) Triglycerides ≥200 mg/dL (≥2.258 mmol/L) (patients ≥18 years of age) or ≥150 mg/dL (≥1.694 mmol/L) (patients <18 years of age) on at least one occasion (12) Cholesterol ≥240 mg/dL (≥6.2064 mmol/L) (patients ≥18 years of age) or ≥200 mg/dL (≥5.172 mmol/L) (patients <18 years of age) on at least one occasion.
Estonian: (12) Triglütseriidid ≥200 mg/dl (≥2,258 mmol/l) (≥18-aastased patsiendid) või ≥150 mg/dl (≥1,694 mmol/l) (<18-aastased patsiendid) vähemalt ühel korral.
English: The pharmacokinetics of sodium valproate and quetiapine were not altered to a clinically relevant extent when co-administered.
Estonian: Naatriumvalproaadi ja kvetiapiini farmakokineetilised omadused ei muutunud samaaegsel kasutamisel kliiniliselt oluliselt.
English: There were no additional safety findings associated with treatment with Seroquel XR for up to 9 months (median 7 months).
Estonian: Keskmine annuse suurus oli 669 mg. Kuni 9-kuulise ravi jooksul (mediaan 7 kuud) SEROQUEL XRga ei ilmnenud ohutusega seotud lisaleide.
English: In one long-term study (up to 2 years treatment) evaluating recurrence prevention in patients with manic, depressed or mixed mood episodes quetiapine was superior to placebo in increasing the time to recurrence of any mood event (manic, mixed or depressed), in patients with bipolar I disorder.
Estonian: Ühes pikaajalises (ravi kestus kuni kaks aastat) retsidiivide ennetamise uuringus, mis viidi läbi mania, segatüüpi ja depressiooni episoodide patsientide hulgas, leiti, et kvetiapiin pikendas aega misiganes meeleoluhäireni (mania, segatüüpi või depressioon) paremini kui platseebo I tüüpi bipolaarse häirega patsientidel.
English: The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine are somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension and dyspepsia.
Estonian: Kõige sagedasemad kõrvalnähud kvetiapiini manustamisel on unisus, pearinglus, suukuivus, kergekujuline jõuetus, kõhukinnisus, tahhükardia, ortostaatiline hüpotensioon ja düspepsia.
English: Perform the following new PASS studies in MDD patients to further characterise the long-term safety and use of quetiapine XR, including the specialist care setting:
Estonian: Müügiloa hoidjad korraldavad järgmised müügiloa väljastamise järgsed ohutusuuringud raskete depressiivhäiretega patsientidel, et täiendavalt iseloomustada ravimi Seroquel XR pikaajalist ohutust ja kasutamist, sh eriravi tingimustes:
English: Levels of TBG were unchanged and in general, reciprocal increases in TSH were not observed, with no indication that quetiapine causes clinically relevant hypothyroidism.
Estonian: Enamasti ei täheldatud TSH kontsentratsiooni tõusu, kliiniliselt olulist hüpotüreoidismi kvetiapiin ei põhjusta.
English: See leaflet for further information.
Estonian: Edasist infot vt pakendi infolehest.
English: In a long-term study in stable schizophrenic patients who had been maintained on Seroquel XR for 16 weeks, Seroquel XR was more effective than placebo in preventing relapse.
Estonian: Pikaajalises uuringus osutus SEROQUEL XR platseebost tõhusamaks haiguse retsidiveerumise ärahoidmisel 16 nädalat SEROQUEL XRi kasutanud stabiilsetel skisofreeniahaigetel.
English: Neuroleptic malignant syndrome has been associated with antipsychotic treatment, including quetiapine (see section 4.8).
Estonian: Antipsühhootilise raviga (k.a kvetiapiin) on seostatud maliigse neuroleptilise sündroomi teket (vt 4.8).
English: Your doctor may suggest you reduce the dose gradually before stopping treatment.
Estonian: Soovitav on ravi katkestada järk-järgult.
English: In patients stabilised on Seroquel immediate release 400 mg to 800 mg, efficacy was maintained when patients were switched to an equivalent daily dose of Seroquel XR given once daily.
Estonian: Patsientidel, kelle seisund oli stabiliseerunud, kasutades SEROQUELi annuses 400 kuni 800 mg, säilis stabiilne seisund ka üleminekul SEROQUEL XR ekvivalentsetele annustele.
English: In vitro CYP inhibition is observed only at concentrations approximately 5 to 50 fold higher than those observed at a dose range of 300 to 800 mg/day in humans.
Estonian: In vitro ilmneb CYP pärssimine alles 5...50 korda kõrgema kontsentratsiooni juures kui see saavutatakse soovitatava annuse (300…800 mg/ööpäevas) manustamisel inimestele.
English: You, or someone in your family, have or have had any heart problems, for example heart rhythm problems or if you are taking any medicines that may have an impact on the way your heart beats.
Estonian: Rääkige oma arstile: - kui teil on terviseprobleeme - kui teil on madal või kõrge vererõhk või kui teil on olnud ajurabandus - kui teil või mõnel teie lähisugulasel on olnud probleeme südamerütmiga või on südamehaigus või probleemid südamega või kui te kasutate ravimeid, mis võivad mõjutada teie südamerütmi - kui teil on kaasasündinud pikenenud QT-intervalli sündroom.
English: ANNEX III SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
Estonian: LISA III RAVIMI OMADUSTE KOKKUVÕTE, PAKENDI MÄRGISTUS JA PAKENDI INFOLEHT
English: In a meta-analysis of atypical antipsychotics, it has been reported that elderly patients with dementiarelated psychosis are at an increased risk of death compared to placebo.
Estonian: Atüüpiliste antipsühhootiliste ravimitega teostatud uuringute metaanalüüsis leiti, et dementsusega seotud psühhoosiga vanemaealistel patsientidel on tõusnud risk suremusele.
English: Approximately 73% of a radiolabelled drug was excreted in the urine and 21% in the faeces with less than 5% of the total radioactivity representing unchanged drug-related material.
Estonian: Ligikaudu 73% radioaktiivsest ravimist eritus uriiniga ja 21 % väljaheitega.
English: In controlled clinical trials there was no difference in the incidence of seizures in patients treated with quetiapine or placebo.
Estonian: Kontrollitud kliinilistes uuringutes ei täheldatud erinevust krambihoogude esinemissageduses kvetiapiiniga ravitud patsientidel ja neil, kes kasutasid platseebot.
English: Venous Thromboembolism (VTE):
Estonian: Venoosne tromboemboolia (1)
English: Based on the above, the benefit risk is considered positive for Seroquel XR as add-on treatment of major depressive episodes in patients with major depressive disorder, who have had suboptimal response to initial antidepressant mono-therapy subject to conditions of the marketing authorisation.
Estonian: Ülaltoodust lähtudes loeti ravimi Seroquel XR kasulikkuse ja riski suhe positiivseks raskete depressiooniepisoodide täiendava ravi korral raskete depressiivhäiretega patsientidel, kes ei reageeri piisavalt esialgsele antidepressandi monoteraapiale müügiloa tingimuste kohaselt.
English: Increases in triglycerides, LDL and total cholesterol, and decreases in HDL cholesterol have been observed in clinical trials with quetiapine (see section 4.8).
Estonian: Kliinilistes uuringutes kvetiapiiniga on esinenud triglütseriidide, LDL-kolesterooli ja üldkolesterooli taseme tõusu ning HDL-kolesterooli taseme langust (vt 4.8).
English: GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, AND PACKAGE LEAFLET
Estonian: RAVIMI OMADUSTE KOKKUVÕTTE JA PAKENDI INFOLEHE MUUTMISE ALUSED
English: Prolactin levels (patients < 18 years of age): >20 ug/L (>869.56 pmol/L) males; >26 ug/L (>1130.428 pmol/L) females at any time.
Estonian: (17) Prolaktiini tase (>18-aastased patsiendid): >20 mcg/l (>869,56 pmol/l) meestel; >30 mcg/l (>1304,34 pmol/l) naistel sõltumata ajahetkest.
English: In two recurrence prevention studies evaluating quetiapine in combination with mood stabilizers, in patients with manic, depressed or mixed mood episodes, the combination with quetiapine was superior to mood stabilizers monotherapy in increasing the time to recurrence of any mood event (manic, mixed or depressed).
Estonian: Kahes retsidiivide ennetamise uuringus, kus hinnati ravimi SEROQUEL koosmõju meeleolu stabiliseerivate ravimitega mania, depressiooni või segatüüpi patsientidel, pikendas SEROQUEL aega järgmise (depressiooni, segatüüpi või mania episoodi) retsidiivini paremini kui ükski meeleolu stabiliseeriv ravim eraldi.
English: - The CHMP concluded on a positive benefit risk ratio for Seroquel XR as add-on treatment of major depressive episodes in patients with major depressive disorder, who have had suboptimal response to initial antidepressant monotherapy further to consideration of the safety profile of Seroquel.
Estonian: - komitee luges ravimi Seroquel XR kasulikkuse ja riski suhte positiivseks raskete depressiooniepisoodide täiendava ravi korral raskete depressiivhäiretega patsientidel, kes ei reageerinud piisavalt esialgsele antidepressandi monoteraapiale; täiendavalt kaaluti ravimi Seroquel ohutusprofiili;
English: In 4 additional clinical trials with quetiapine, with a duration of 8 weeks in patients with moderate to severe depressive episodes in bipolar I or bipolar II disorder, Seroquel IR 300 mg and 600 mg was significantly superior to placebo treated patients for the relevant outcome measures: mean improvement on the MADRS and for response defined as at least a 50% improvement in MADRS total score from baseline.
Estonian: Veel neljas 8-nädalalises kliinilises uuringus kvetiapiiniga I ja II tüüpi bipolaarse häirega keskmise raskusega ja raske depressiivse episoodiga patsientide hulgas oli SEROQUEL annuses 300 ja 600 mg oluliselt parem olulistes tulemusnäitajates: keskmine MADRS-skaala tulemuse paranemine ning vähemalt 50% MADRS kogupunktisumma paranemine võrreldes algtasemega.
English: The incidence of relapse was 14.2% for Seroquel XR treated patients and 34.4% for placebotreated patients.
Estonian: Retsidiiv tekkis 14,2%-l ravirühmas ning 34,4%-l platseebo rühmas.
English: • add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see Section 5.1).
Estonian: Depressiooni lisaravi, kui monoteraapia antidepressandiga ei ole andnud optimaalset ravivastust (vt 5.1).
English: Interactions: See also section 4.5.
Estonian: Vt ka 4.5.
English: Quetiapine exhibits minimal dystonic liability in haloperidol-sensitised or drug-naive Cebus monkeys after acute and chronic administration.
Estonian: Nii pärast akuutset kui ka kroonilist manustamist avaldab kvetiapiin minimaalset düstoonilist kalduvust haloperidooliga sensibiliseeritud või ravim-naiivsetel Cebus ahvidel.
English: Prior to initiating treatment, clinicians should consider the safety profile of SEROQUEL XR (see Section
Estonian: Ravi alustades tuleb arvesse võtta Seroquel XR ohutusandmeid (vt 4.4).
English: • Abnormal muscle movements.
Estonian: - söögiisu tõus; - ebanormaalne lihaste liikuvus.
English: However, survival has also been reported following acute overdoses of up to 30 grams.
Estonian: Siiski on ägedate üleannustamiste korral patsiendid jäänud elama kuni 30 g kvetiapiini manustamisel.
English: In shorter-term placebo controlled clinical studies of patients with major depressive episodes in bipolar disorder an increased risk of suicide-related events was observed in young adults patients (younger than 25 years of age) who were treated with quetiapine as compared to those treated with placebo (3.0% vs. 0%, respectively).
Estonian: Lühemaajalistes kontrollitud kliinilistes uuringutes depressiooniga patsientide hulgas ilmnes ravirühma noortel täiskasvanud patsientidel (alla 25-aastased) tõusnud risk suitsiidiga seotud sündmusteks võrreldes platseeboga (vastavalt 3,0% ja 0%).
English: Taking these findings into consideration, the benefits of the treatment with quetiapine need to be balanced against the safety risks for the patient.
Estonian: Arvestades neid leide, peab kvetiapiinravi määramisel kaaluma riski/kasu suhet.
English: The average molar dose fraction of free quetiapine and the active human plasma metabolite norquetiapine is <5% excreted in the urine.
Estonian: Molaarselt arvutatuna eritub uriiniga vähem kui 5% vabast kvetiapiinist ja inimese plasmas leiduvast aktiivsest metaboliidist norkvetiapiinist.
English: In short-term placebo-controlled trials with Seroquel in paediatric patients with bipolar mania, the incidence of suicide related events was 1.0% (2/193) for quetiapine and 0% (0/90) for placebo in patients <18 years of age.
Estonian: Pediaatrilistel bipolaarse mania patsientidel (<18-aastased) läbiviidud lühiajalistes platseebo kontrolliga kliinilistes uuringutes oli suitsiidiga seotud sündmuste sagedus 1,0% (2/193) kvetiapiini rühmas ja 0% (0/90) platseebo rühmas.
English: Tell your doctor immediately if you experience:
Estonian: Niipea kui võimalik, informeerige oma arsti, kui allpool loetletud kõrvaltoimed teid häirivad:
English: There is an increased risk of adverse events at higher doses.
Estonian: Kõrgemate annuste kasutamisel suureneb risk kõrvaltoimete tekkeks.
English: Patients with hepatic impairment should be started on 50 mg/day.
Estonian: Maksakahjustusega patsientidel tuleks ravi alustada annusest 50 mg/ööpäevas.
English: Elevations in total cholesterol (predominantly LDL cholesterol) 12, Decreases in HDL cholesterol18, Weight gain9
Estonian: Triglütseriidide kontsentratsiooni tõus veres (12) Üldkolesterooli (peamiselt LDL-kolesterooli) tõus veres
English: In comparison, a light meal had no significant effect on the Cmax or AUC of quetiapine.
Estonian: Madala rasvasisaldusega toit seevastu Cmax ja AUCväärtusi ei mõjutanud.
English: Smaller decreases in total T3 and reverse T3 were seen only at higher doses.
Estonian: Vaid ravimi suuremate annuste kasutamisel täheldati üld- ja pöörd-T3 langust.
English: In a clinical trial, in patients with depressive episodes in bipolar I or bipolar II disorder, 300 mg/day Seroquel XR showed superior efficacy to placebo in reduction of MADRS total score.
Estonian: Kliinilises uuringus I ja II tüüpi bipolaarse häirega seotud depressiivse episoodiga patsientide hulgas oli SEROQUEL annuses 300 mg/ööpäevas MADRS kogupunktisumma vähendamisel platseebost parem.
English: As with other antipsychotics, weight gain, syncope, neuroleptic malignant syndrome, leucopenia, neutropenia and peripheral oedema, have been associated with quetiapine.
Estonian: Kvetiapiini, nagu teistegi antipsühhootikumide kasutamisega, võivad kaasneda kaalutõus, teadvuskaotushood, maliigne neuroleptiline sündroom, leukopeenia, neutropeenia ja perifeerne turse.
English: If you have any further questions on the use of this product, ask your doctor or pharmacist.
Estonian: Kui kahtlete milleski, küsige nõu oma arstilt või apteekrilt.
English: • Increase in blood pressure.
Estonian: • depressioon.
English: In placebo-controlled monotherapy trials in patients with a baseline neutrophil count ≥ 1.5 X 109/L, the incidence of at least one occurrence of neutrophil count <1.5 X 109/L, was 1.72% in patients treated with quetiapine compared to 0.73% in placebo-treated patients.
Estonian: Kõikides kontrollitud kliinilistes monoteraapia uuringutes langes neutrofiilide väärtus alla 1,5 X 109/l 1,72%-l patsientidest, kelle algne neutrofiilide väärtus oli vähemalt 1,5 X 109/l, võrreldes 0,73%-ga kontrollrühmas.
English: Hepatitis 6
Estonian: Ikterus (6) Hepatiit (6)
English: Lipids:
Estonian: Lipiidid
English: Severe Neutropenia:
Estonian: Raskekujuline neutropeenia
English: Seroquel data in combination with divalproex or lithium in acute moderate to severe manic episodes at 3 and 6 weeks is limited; however, combination therapy was well tolerated.
Estonian: Andmed SEROQUELi kohta manustatuna koos liitiumpreparaadi või naatriumvalproaadiga ägeda keskmise raskusega või raske mania episoodi raviks 3 ja 6 nädala jooksul on piiratud.
English: Seizures:
Estonian: Uuringud:
English: Fatal outcome has been reported in clinical trials following an acute overdose at 13.6 grams, and in post-marketing on doses as low as 6 grams of Seroquel alone.
Estonian: Üksikjuhul on teatatud 13,6-grammise üleannuse võtmisele järgnenud surmast kliinilise uuringu ajal.
English: Fever, severe muscle stiffness, sweating or a lowered level of consciousness (a disorder called “neuroleptic malignant syndrome”).
Estonian: Teatage viivitamatult oma arstile, kui teil tekib: - palavik, tugev lihasjäikus, higistamine või teadvuse hägunemine (maliigne neuroleptiline sündroom).
English: 50 mg, 150 mg 200 mg, 300 mg and 400 mg tablets
Estonian: 50, 150, 200, 300 ja 400 mg tabletid
English: As with other antipsychotics, caution is recommended when treating patients with a history of seizures (see Section 4.8).
Estonian: Nii nagu teiste antipsühhootikumide korral, soovitatakse ka SEROQUEL XRi manustades olla eriliselt tähelepanelik, kui ravitakse varem krambihooge kogenud patsiente (vt 4.8).
English: In individual patients, in the event of tolerance concerns, clinical trials have indicated that dose reduction to a minimum of 200 mg could be considered.
Estonian: Kliinilised uuringud on näidanud, et üksikutel patsientidel, kellel on probleem ravitaluvusega, võib annust langetada tasemele 200 mg ööpäevas.
English: • Do not stop taking your tablets even if you feel better, unless your doctor tells you.
Estonian: - ravimi manustamist ei tohi ise lõpetada ka siis, kui tunnete end hästi.
English: In clinical trials, no additional benefit was seen in the 600 mg group compared to the 300 mg group (see section 5.1).
Estonian: Kvetiapiinil on tõestatud depressioonivastane toime annuses 300 mg ja 600 mg. Siiski, 600 mg kasutamisel lühiajalises ravis ei esinenud ravitulemuse märgatavat paranemist võrreldes 300 mg annuse kasutamisega (vt 5.1).
English: Given its primary central nervous system effects, quetiapine may interfere with activities requiring mental alertness.
Estonian: Kvetiapiin võib oma toime tõttu kesknärvisüsteemile segada tähelepanu nõudvaid tegevusi.